Introduction
============

To date, there are no known methods for preventing acute kidney injury after cardiac surgery. Increasing evidence suggests that erythropoietin (EPO) has renal anti-apoptotic and tissue protective effects \[[@B1]\], and in animal models a single high dose of EPO has been shown to ameliorate reperfusion injury after ischemia \[[@B2]\]. However, recent human studies have shown conflicting results. We aimed to study the effect of a single high dose of EPO preoperatively on renal function after coronary artery bypass grafting (CABG) in patients with preoperative impaired renal function.

Methods
=======

This single-centre, randomized, double-blind, placebocontrolled study included 75 patients scheduled for CABG with preexisting renal impairment (estimated glomerular filtration rate based on p-cystatin C \<60 ml/minute and \>15 ml/minute). The patients either received a single high dose of EPO (400 lU/kg) or placebo preoperatively. The primary endpoint was renal protection evaluated by p-cystatin C at the third postoperative day compared with the preoperative values. Incidence of acute kidney injury and other renal biomarker changes were among secondary endpoints.

Results
=======

There was no significant difference on the third postoperative day for p-cystatin C levels (2.1 ± 0.8 mg/l for the study group and 1.9 ± 0.5 mg/l for the control group, *P*= 0.51). There were no significant differences in other renal biomarkers or measures between the groups (p-NGAL, p-creatinine, p-urea, and estimated glomerular filtration rate). There were no other differences in outcome variables between the groups.

Conclusion
==========

Intravenous administration of a single high dose (400 IU/ kg) of EPO did not have a renal protective effect in patients with reduced kidney function undergoing coronary artery bypass surgery.
